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Abstract 
Background: In many malaria‑endemic, sub‑Saharan African countries, existing pharmacovigilance systems are not 
sufficiently operational to document reliably the safety profile of anti‑malarial drugs. This study describes the implan‑
tation of a community‑based pharmacovigilance system in Côte d’Ivoire and its use to document the safety of ASAQ 
Winthrop® (artesunate–amodiaquine).
Methods: This prospective, longitudinal, descriptive, non‑comparative, non‑interventional study on the use of 
artesunate–amodiaquine in real‑life conditions of use was conducted in seven Community Health Centres of the 
Agboville district in Côte d’Ivoire. Twenty trained Health Centre employees and 70 trained community health workers 
were involved in data collection in the field. All patients with suspected uncomplicated falciparum malaria, seeking 
treatment at one of the participating Health Centres, and treated with artesunate–amodiaquine could be enrolled. 
Two visits were planned, one for inclusion at the Health Centre and a second at home, performed by a community 
health worker 3–10 days after the inclusion visit. Administration of artesunate–amodiaquine was unsupervised. 
Adverse events (AEs) were documented at the home visit or during any unexpected visit to the Health Centre or to 
the hospital and coded and adjudicated by a local pharmacovigilance committee. Symptoms suggestive of hepatic 
failure, severe neutropaenia, extrapyramidal disorders and retinopathy were considered a priori as AEs of special 
interest.
Results: Some 15,228 malaria episodes in 12,198 patients were evaluated; 2545 AEs were documented during 1978 
malaria episodes (13.0%). The most frequently observed events were asthenia (682 cases), vomiting (482 cases) and 
somnolence (174 cases). Most reported AEs were of mild or moderate intensity and resolved without corrective treat‑
ment. One‑hundred and five (105) AEs reported during 100 episodes (0.7%) were considered as serious. Three serious 
cases of transient extrapyramidal disorders, identified as AEs of special interest were reported in three patients.
Conclusion: The fixed dose artesunate–amodiaquine combination ASAQ Winthrop® for the unsupervised treatment 
of uncomplicated falciparum malaria under real‑life conditions of care in Côte d’Ivoire is well tolerated. The study 
emphasizes the interest of involving properly trained community health workers to collect pharmacovigilance data in 
the field in order to document rare AEs.
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Background
Since 2001, artemisinin-based combination therapy 
(ACT) is recommended by the World Health Organiza-
tion (WHO) as the mainstay of treatment of uncom-
plicated falciparum malaria [1, 2]. Between 2004 and 
2007, a fixed-dose, combined formulation containing 
artesunate (AS) and amodiaquine (AQ) in a single tablet, 
was developed by Sanofi in partnership with Drugs for 
Neglected Disease initiative (DNDi) (ASAQ Winthrop®) 
[3]. A large number of clinical trials [4] have shown that 
the ASAQ fixed-dose combination is effective in clearing 
Plasmodium falciparum parasites from infected individ-
uals [5–13].
In Côte d’Ivoire, 43% of consultations in Health Centres 
are motivated by suspected malaria and effective man-
agement is a major public health issue [14]. A National 
Malaria Control Programme (NMCP) was established in 
1996 with a number of specific policy areas covering pre-
vention, treatment, education, and infrastructure. Nota-
bly, in 2007, systematic provision of ACT in local Health 
Centres (HCs) was adopted, and free or fixed combina-
tions of AS and AQ were proposed as first-line treatment, 
with artemether–lumefantrine combinations as second-
line treatment for uncomplicated falciparum malaria. 
At the time of the introduction of ASAQ Winthrop®, 
Sanofi and the DNDi wanted to ensure that appropriate 
post-marketing data were available as quickly as possible 
regarding the safety and effectiveness of this anti-malarial 
treatment in the field. Existing pharmacovigilance sys-
tems in many endemic sub-Saharan African countries 
were not sufficiently operational to document reliably the 
safety profile of this drug. For this reason, a deployment 
monitoring plan for ASAQ Winthrop® was designed to 
provide quality efficacy and safety data through a variety 
of pro-active studies, each providing different types of 
data. These studies have ranged from randomized, com-
parative, clinical trials in a limited number of patients 
treated under well-controlled conditions, to longitudi-
nal, randomized cohorts to assess safety and efficacy in 
repeated administration, and finally to large-scale stud-
ies assessing the drug’s safety in ‘real-life’ conditions [15]. 
As part of this programme, the Agboville health district 
in Côte d’Ivoire was chosen as the location of a large, 
naturalistic, observational study to collect safety data on 
ASAQ Winthrop® treatment under conditions of real-life 
use.
Before implementation of this study, a pharmacovigi-
lance training programme for selected HC employees and 
community health workers (CHWs) was set up in order 
to optimize data collection. This programme was imple-
mented through a partnership between Côte d’Ivoire 
Health Ministry, National Research Institutes (Institut 
Pierre Richet/Institut National de la Santé Publique, Côte 
d’Ivoire), University Departments of Côte d’Ivoire, DNDi, 
Medicines for Malaria Venture (MMV) and Sanofi.
The primary objective of the study was to determine 
the safety of ASAQ Winthrop® in real-life conditions of 
care in Côte d’Ivoire through the collection of clinical 
safety data. It was designed to evaluate at least 15,000 
treated malaria episodes in order to permit detection 
of rare adverse events (AEs), which may have escaped 
detection in previous smaller, interventional, clini-
cal trials. Secondary objectives included evaluation of 
the safety profile of ASAQ Winthrop® in sub-groups of 
patients defined according to parasitaemia status, and to 
assess patient compliance.
Methods
This was a prospective, longitudinal, descriptive, non-
comparative, non-interventional study on the use of 
ASAQ Winthrop® in real-life conditions of use, con-
ducted in HCs of the Agboville district, located approxi-
mately 80  km north of Abidjan, Côte d’Ivoire, between 
February 2010 and October 2013. It was originally 
planned to perform the study over a 2-year period in 
only four HCs, but this was extended to 3 years and seven 
centres due to slow enrolment and to the outbreak of the 
2010–2011 second Ivoirian Civil War, which threatened 
to disrupt the conduct of the study.
Over the course of the study, 20 trained employees 
working in HCs who receive patients for consultation and 
70 trained field CHWs who visit patients in their homes 
were involved in data collection, and regularly supervised 
by the investigator team. To allow proper collection of 
safety data, two training sessions were organized for all 
participating HC employees and CHWs, once prior to 
implementation, and once during the study. This training 
related to the fundamental principles of pharmacovigi-
lance, specific study procedures for collecting safety data 
and recognition of symptoms evoking AEs of special 
interest (AESI) for ASAQ Winthrop®. The CHWs were 
provided with bicycles and the HCs with motorcycles to 
enable all patients to be visited in their territory rapidly 
and effectively.
Implementing partners
This study was implemented through a partnership that 
included the NMCP, the pharmacovigilance unit of the 
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Pharmacology Department of Medical Sciences of the 
University of Abidjan, and the pharmacovigilance direc-
tor of the Drug and Pharmacy Authority of the Côte 
d’Ivoire. Local community leaders were also involved to 
ensure successful implementation of the study in their 
territory. The study was coordinated by SBA, with the 
assistance of two co-investigators, an Independent Sci-
entific Committee, a Pharmacovigilance Committee, a 
local Scientific Committee and a local Pharmacovigilance 
Committee. The role of the different study partners in the 
collection and analysis of the data is illustrated in Addi-
tional file 1.
Eligibility criteria
All patients with suspected uncomplicated malaria who 
presented to the study centres, were able to take oral 
medication, were prescribed ASAQ Winthrop® and who 
provided signed informed consent were eligible. During 
the course of the study in May 2011, national guidelines 
for malaria management changed from malaria diagno-
sis based on clinical suspicion only to a requirement for 
confirmation by a positive rapid diagnostic test (RDT) for 
antibodies against histidine-rich protein 2. The inclusion 
criteria for the study were modified accordingly. Exclu-
sion criteria related to known allergy to AS or AQ, known 
pregnancy, severe malaria, visual disorders suggestive 
of retinopathy, and hepatic or haematological disorders 
occurring during previous treatment with AQ.
Study design and procedures
All patients with suspected uncomplicated falciparum 
malaria seeking treatment at one of the participating HCs 
and treated with ASAQ Winthrop® could be enrolled. 
All patients attending a participating HC were entered 
into the registry of the HC and all patients presenting 
suspected malaria were recorded in a specific screening 
registry, which documented date of visit, age and gen-
der of the patient, village or district of origin, and, after 
May 2011, the result of RDT. If the patient met the selec-
tion criteria to participate in the study, and provided 
informed consent, a patient number was generated and 
a case report form (CRF) established; otherwise, the rea-
son for non-participation was documented in the reg-
istry. Two visits were scheduled per patient, a first visit 
for inclusion at the HC and a second follow-up visit 
at home performed by a CHW 3–10  days after the ini-
tial visit. Additional unplanned visits for safety issues at 
the HC within 28 days of treatment initiation were also 
documented.
At the inclusion visit, demographic features (age, 
gender, weight), concomitant diseases, concomitant 
medication, previous use of traditional medication or 
anti-malarial drugs in the previous 2 weeks, and clinical 
features were documented. A finger-prick blood sample 
was taken using a vaccinostyle for a thick blood smear, 
which was to be read later centrally. Patients who met 
inclusion criteria were provided with a blister of ASAQ 
Winthrop® covering the full 3-day treatment. At the fol-
low-up visit, CHWs asked patients whether any clinical 
signs had appeared or worsened since the inclusion visit 
and, if this was the case, documented the signs or symp-
toms reported, date of onset, intensity, and outcome. In 
the case of detection of an AE requiring medical atten-
tion, the patient was addressed to the HC where fur-
ther information was collected on seriousness, severity 
and management. CHWs counted and documented any 
ASAQ Winthrop® tablets remaining in the blister pack 
provided at the HC. Information was collected on any 
other treatments taken since the inclusion visits, includ-
ing treatments prescribed at the HC and traditional med-
icines. Patients were informed of the need to re-contact 
the HC in case of onset or worsening of any symptoms 
appearing after the visit of the CHW.
Treatment
ASAQ was prescribed to eligible patients as oral tablets 
(ASAQ Winthrop®) to be taken once a day for 3  days 
using the recommended treatment regimen. Adminis-
tration of ASAQ Winthrop® was unsupervised. The dose 
was adjusted according to patient’s age, within four age/
weight ranges as specified in the ASAQ Winthrop® pre-
scribing information.
Determination of parasitaemia
Two thick blood smears were prepared from the blood 
sample taken at the inclusion visit and stained with a 
May-Grünwald-Giemsa solution for subsequent central-
ized reading to determine parasite density. One slide was 
sent to Abidjan for reading and the second was kept in 
the HC as back-up. All blood smears were provided to 
a central laboratory (Institut Pierre Richet, Abidjan and 
Bouaké, Côte d’Ivoire) where they were read by qualified 
personnel according to standard laboratory procedures. 
Parasite density was determined by reading 200 high-
powered fields on the thick blood smear and counting the 
number of asexual parasites and white blood cells. Slides 
were considered negative if no parasite was detected after 
reading 200 high-powered fields. The presence and den-
sity of gametocytes was also determined. A randomly 
selected 10% sample of the thick smears was double-read 
for quality control.
Safety evaluation
Safety was evaluated through documentation of AEs. All 
AEs documented at the follow-up visit or during a sub-
sequent visit to the HC were coded using the Medical 
Page 4 of 12Assi et al. Malar J  (2017) 16:8 
Dictionary for Regulatory Activities (MedDRA) version 
17.0 and classified by severity and by seriousness. All 
AEs were reviewed centrally by the local pharmacovigi-
lance committee for attribution of causality, according to 
a decisional algorithm based on French [16] and WHO 
[17] methods. These two methods differ in being more 
(French) or less (WHO) structured and in the criteria 
considered (such as rechallenge, previous exposure or 
concomitant medication) [18]. Hospital staff in Agbo-
ville were asked to report to the investigator team any 
cases of hepatotoxicity or agranulocytosis occurring in 
study participants who attended hospital. Any corrective 
treatment prescribed at the HC or at hospital was docu-
mented. Symptoms suggestive of hepatic failure (such as 
jaundice or severe pruritus), severe neutropaenia (such as 
mouth ulcerations), extrapyramidal disorders (abnormal 
movements, tongue protrusion) and retinopathy (blurred 
vision) were considered a priori as AESIs, and these were 
handled in the same way as serious AEs (SAEs). Proce-
dures describing the management of identified SAEs or 
AESI by the HC personnel were validated by the infec-
tious disease department of Treichville Hospital in Abid-
jan and outcome followed up with the relevant HC. All 
SAEs and AESIs were immediately communicated to the 
National Pharmacovigilance centre for Côte d’Ivoire and 
reviewed by the study Pharmacovigilance Committee. 
All relevant important information from this review was 
then forwarded to the members of the Independent Sci-
entific Committee. Information on other AEs was com-
municated to the National Pharmacovigilance centre at 
regular intervals (approximately two-monthly) following 
causality review.
In the case of pregnancy being identified by midwives 
of the HCs in patients who had taken ASAQ Winthrop®, 
women were followed up until delivery and the outcome 
reported to the Sanofi pharmacovigilance department.
Statistical analysis
This was not a hypothesis-testing study and no tar-
get sample size was determined a priori. The study was 
intended to enrol all patients attending a participating 
malaria treatment centre and prescribed ASAQ Win-
throp®. It was estimated that documentation of at least 
15,000 malaria episodes should allow identification of 
rare AEs occurring with an incidence of one in 5000. 
Safety analysis was performed on episodes experienced 
by all patients who had provided signed informed con-
sent and taken at least one dose of ASAQ Winthrop®.
Quality control
Medication blisters were collected at the follow-up 
visits by CHWs and then filed in the CRF. In order to 
assess compliance, the number of remaining tablets was 
recorded in the CRF. Completion of all CRFs and the data 
therein, including verification of the number of remain-
ing tablets, were checked by a monitor at the time of col-
lection. The investigator team visited and inspected all 
participating HCs on a quarterly basis to ensure compli-
ance with the study protocol. As a quality control meas-
ure, approximately 10% of the CRFs collected in each HC 
were checked against the centre’s patient registry. When 
inconsistencies were detected, the proportion of CRFs to 




Patient disposition is illustrated in Fig. 1. Overall, 36,388 
malaria episodes in patients attending a participat-
ing centre were screened for eligibility. Of these, 15,228 
episodes (41.8%) in 12,198 patients met the eligibility 
criteria. The principal reasons for non-eligibility were a 
negative RDT (32% of attacks screened), severe malaria 
(19%) and patients who could not be followed up (17%). 
Of the 12,198 enrolled patients, 10,294 (84.4%) experi-
enced one identified episode of malaria, 1258 (10.3%) 
two episodes, 374 (3.1%) three episodes and 272 (2.2%) 
patients more than three episodes over the study period. 
Sixty-seven of the episodes in 67 patients (0.5%) could 
not be assessed after treatment and were excluded from 
the safety population. The reasons for non-assessment 
were loss to follow-up (N  =  36; 53.7%), treatment not 
received by the patient (N  =  16; 23.9%), treatment not 
taken by the patient (N = 12; 17.9%) and loss of the CRF 
(N = 3; 4.5%).
Of the 15,228 eligible episodes, 51.5% occurred dur-
ing the rainy season and 48.5% during the dry season. 
The mean number of episodes was 1.2 ± 0.7 per patient 
(median 1; range 1–11), during the rainy season and 
0.6 ± 0.7 episodes per patient (median 1; range 1–6) dur-
ing the dry season.
Patient characteristics
Patient characteristics at inclusion are presented by 
malaria episode in Table  1. Nearly two-thirds of these 
episodes (64.7%) occurred in patients under 6  years of 
age (median age 3 years) and the gender ratio was close 
to unity. All episodes with available data (N  =  15,225) 
were associated with signs or symptoms consistent with 
malaria, most frequently fever (87.3%); other symptoms 
were documented for <20% of episodes. Some of these 
symptoms were reported more often as signs of malaria 
rather than of concomitant disease, notably headache 
(19.7 vs 0.1%), vomiting (15.2 vs 1.4%), asthenia (9 vs 
0.2%), and joint ankylosis/arthralgia (8.7 vs 0.2%), while 
others were more often reported as signs of concomitant 
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disease (cough/productive cough: 21.6 vs 0.1%) and, 
more surprisingly, anaemia (20.7 vs 1.8%). No difference 
was observed in the nature or frequency of presenting 
symptoms between episodes occurring during the rainy 
season and those occurring during the dry season.
A readable thick blood smear was obtained for 14,634 
malaria episodes (96.1%) and these were positive for P. 
falciparum in 76.5% of cases. The diagnosis of malaria 
was more frequently confirmed from the blood smears 
(p < 0.001) for episodes occurring during the rainy season 
(75.3% of episodes) compared to the dry season (71.6%). 
No difference was observed in the nature or frequency 
of presenting symptoms between patients with or with-
out parasites on blood smear. Administration of tradi-
tional medications prior to enrolment was documented 
in 16.5% of the episodes. At least one concomitant treat-
ment was prescribed at inclusion in almost all episodes 
(99.5%), most commonly antipyretics (90.5%), systemic 
antibiotics (37.2%), antiparasitic medicines (28.6%), and 
iron preparations (25.7%).
Treatment compliance
As assessed by questioning and by counting remain-
ing tablets, ASAQ Winthrop® was taken completely 
for 14,736 out of 15,161 malaria episodes [97.2% (95% 
CI 96.9–97.5%)]. The most frequent reason for non-
compliance was treatment discontinuation due to the 
occurrence of an AE (180/425 cases). The dose of ASAQ 
Winthrop® prescribed was appropriate for the patient’s 
age or weight in the majority of episodes (98.6% for age 
and 86.1% for weight).
Adverse events
All but 36 episodes benefitted from a follow-up home 
visit by a CHW. Overall, 2545 AEs were documented 
during 1978 of 15,161 malaria episodes (13.0%) during 
the course of the study (Table  2). The most frequently 
observed AEs were asthenia (682 cases; 4.5%), vomit-
ing (482 cases; 3.1%) and somnolence (174 cases; 1.1%). 
Malaria was reported as an AE during 39 episodes. Of 
these AEs, 105 (4.1%) reported during 100 episodes 
(0.7%) were considered serious. The most commonly 
observed SAEs were malaria cases (29 episodes; 0.2%), 
anaemia (28 episodes; 0.2%) and gastroenteritis (7 epi-
sodes; <0.1%); no other SAE was reported more than 
five times; no SAE was considered as a new signal. The 
majority of AEs were mild (1449 events during 1225 epi-
sodes; 56.9%) or moderate (942 events during 771 epi-
sodes; 37%) in intensity. Of the severe AEs (6.1%), the 
most frequently reported were malaria (N  =  26; 0.2%), 
anaemia (N = 29; 0.2%), asthenia (N = 17; 0.1%), vomit-
ing (N = 13; 0.1%) and pyrexia (N = 9; 0.1%).
Twenty-two deaths, none considered potentially related 
to the study drug, were reported. Three AESIs, all involv-
ing cases of extrapyramidal disorders, were reported in 
three patients. Two of these patients had also received 
djanougbokpè from a folk healer. This is a mixture of 
roots, leaves or bark of different plants with purgative 
properties, which is traditionally used for the treatment 
of malaria in West African societies. The exact compo-
sition of djanougbokpè may vary from one folk healer 
to another. The other patient received a Chinese herbal 
medicine whose composition was not identified on the 
Episodes screened 
N = 36 388 
Episodes included 
N = 15 228 (41.8%) 
Episodes evaluated 
N = 15 161 (99.5%) 
21 160 Screening failures 
67 Not evaluable 
Loss to follow-up: 36 
Treatment not received: 16 
Treatment not taken: 12 
Loss of CRF: 3 
Enrolled paents 
N = 12 198 
Fig. 1 Patient disposition. CRF case report form
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packet. All cases resolved successfully following correc-
tive treatment with intravenous diazepam. One of these 
patients was unintentionally rechallenged with ASAQ 
Winthrop® during a subsequent malaria episode two 
months later without re-appearance of the symptoms.
Most AEs occurred early, during the 3  days of ASAQ 
Winthrop® treatment. The mean time to onset of the 
AEs after the first administration of ASAQ Winthrop® 
was 1.3 ± 1.9 days. Some of these events were recorded 
as AEs retrospectively at the time of the home visit, even 
though they had appeared soon after administration of 
ASAQ Winthrop®. The distribution of AEs according 
to the time of the home visit is presented in Additional 
file  2. More AEs were reported when the home visit by 
the CHW was made soon after treatment initiation, 
although some AEs were recorded even when the home 
visit was performed 10 days later. It should be noted that 
over 80% of the home visits were made between 3 and 
6 days (inclusive) after treatment initiation.
Potentially ASAQ-related AEs (N  =  929; 36.5% of all 
AEs) were reported during 837 episodes (5.5%). The most 
frequent of these are listed in Table  3. Only asthenia, 
somnolence, vomiting, and dizziness were reported at an 
incidence of over one case per 1000 episodes. Of these 
potentially ASAQ-related AEs, 11 (1.2%) were serious, 
of which seven were also rated as severe. These ASAQ-
related SAEs are listed in Table 4. All potentially related 
SAEs resolved spontaneously or after treatment (the 
three cases of extrapyramidal disorder and one case of 
asthenia). In addition, 15 potentially related, non-serious 
AEs were rated as severe, principally asthenia (five cases), 
all of which resolved. Furthermore, eight non-serious, 
non-severe AEs had not resolved by the end of the obser-
vation period and a further five required corrective treat-
ment. A full list of potentially ASAQ-related AEs that 
were serious, severe, unresolved, or that required treat-
ment is provided in Additional file 3. 
Regarding outcome, 2452 of the 2545 AEs resolved sat-
isfactorily (96.3%) without sequelae. In addition, 39 AE 
were improving at the time of last follow-up. One patient 
presented a non-serious skin rash which left marks and 
scars. Twenty-four SAEs during 22 episodes (0.1%) were 
fatal and these are listed in Table 4. None of these fatal 
AEs was considered possibly related to treatment with 
ASAQ Winthrop®.
Adverse events as a function of parasitaemia
The incidence of AEs was compared between malaria 
episodes with parasitaemia detected on thick blood 
smears, unconfirmed malaria episodes without detect-
able parasitaemia, and episodes without available parasi-
taemia results (poor quality of blood smear preparation, 
blood smear not performed or destroyed). No statistically 
significant differences in the incidence or nature of AEs, 
SAEs or potentially ASAQ-related AEs were observed 
between the three sub-groups (Table 5).
Discussion
This large, naturalistic, observational study was designed 
to monitor the safety of ASAQ Winthrop® under condi-
tions of every day care in malaria treatment centres in 
Table 1 Characteristics of malaria episodes
The N numbers in italics refer to the number of episodes for which the variable 
of interest was documented
a Frequency counts correspond to number of episodes, since the same patient 
may have experienced more than one episode. Certain symptoms documented 
from self-report, such as pain, headache and dizziness, could not be ascertained 
in young children
N = 15,228
Age (years) N = 15,225
 Mean ± SD 8.9 ± 13.3
 Median [range] 3 [1–90]
Age by class N = 15,225
 ≤1 month 2 (<0.01%)
 2–11 months 2111 (13.9%)
 1–5 years 7740 (50.8%)
 6–13 years 2581 (17.0%)
 ≥14 years 2791 (18.3%)
Gender N = 15,225
 Female 7582 (49.8%)
 Male 7643 (50.2%)
Weight (kg) N = 15,221
 Mean ± SD 21.6 ± 18.9
 Median [range] 13 [2–116]
Weight by class (kg) N = 15,221
 <4.5 35 (0.2%)
 4.5 to <9 2704 (17.8%)
 9 to <18 7241 (47.6%)
 18 to <36 2278 (15.0%)
 ≥36 2963 (19.5%)
Clinical signs and symptomsa N = 15,225
 Fever 13,294 (87.3%)
 Hyperthermia 1608 (10.6%)
 Asthenia 1373 (9.0%)
 Chills 244 (1.6%)
 Headache 3005 (19.7%)
 Dizziness 228 (1.5%)
 Vomiting 2316 (15.2%)
 Diarrhoea 589 (3.9%)
 Abdominal pain 316 (2.1%)
 Decreased appetite/anorexia 2901 (19.1%)
 Joint ankylosis 1223 (8.0%)
 Anaemia 273 (1.8%)
Parasitaemia N = 14,634
 Positive thick blood smears 11,192 (76.5%)
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Côte d’Ivoire. The study was successfully implemented 
and the target sample size achieved. This illustrates the 
feasibility of such studies for monitoring anti-malarial 
treatments in West Africa and to complement ‘pas-
sive’ pharmacovigilance systems. The study population 
was principally composed of young children, with 65% 
of the sample being under 6 years of age, which reflects 
the epidemiology of malaria in many sub-Saharan Afri-
can countries [19]. The relatively low rates of multiple 
infections over the course of the study can be attributed 
to the design of the study. Since this was not a longitu-
dinal study aimed at investigating multiple malaria epi-
sodes, patients were not required to attend the same 
study HCs for consecutive malaria episodes. Compliance 
with treatment was high in spite of the absence of super-
vised administration of ASAQ Winthrop®. AEs were 
documented in 13% of >15,000 individual treated malaria 
episodes in >12,000 patients over a period of 3½  years. 
Overall, treatment with ASAQ Winthrop® was found 
to be well tolerated and the nature of AEs reported was 
consistent with the known safety profile of ASAQ Win-
throp®. Most reported AEs were not severe and resolved 
without the need for medical intervention.
Table 2 Overview of adverse events
Number of adverse events Number of episodes Incidence
Any adverse event 2545 1978 13.0% [12.5%; 13.6%]
Serious adverse events 105 100 0.7% [0.5%; 0.8%]
Severe adverse events 154 126 0.8% [0.7%; 1.0%]
Adverse events of special interest 3 3 <0.1%
Fatal serious adverse events 24 22 0.2% [0.1%; 0.2%]
Potentially ASAQ‑related adverse events 929 837 5.5% [5.2%; 5.9%]
Adverse events requiring corrective treatment 157 105 0.7% [0.6%; 0.8%]
Table 3 Potentially ASAQ-related adverse events
Only individual adverse events reported during more than ten malaria episodes are listed in this table
a Calculated with respect to the 15,228 documented malaria episodes
Number of adverse events Number of episodes Incidencea
Any potentially ASAQ‑related adverse event 929 837 5.5%
Asthenia 410 410 2.7
Somnolence 134 134 0.9
Vomiting 89 89 0.6
Dizziness 84 84 0.6
Diarrhoea 21 21 0.1
Insomnia 13 13 0.1
Abdominal pain 12 12 0.1
Pruritus 26 26 0.2
Decreased appetite 28 28 0.2
Cough 13 13 0.1
Table 4 Treatment-related or fatal serious adverse events
SAE serious adverse events
a 22 patients died, two of whom presented two SAEs at the time of death 
(anaemia with sepsis in one patient and diarrhoea with dehydration in the 
other). A further patient presented with malaria (serious) and cough (non-
serious) at the time of death
SAEs considered related to ASAQ 11
 Asthenia 4
 Vomiting 3
 Extrapyramidal disorders 3
 Dyspnoea 1
Fatal SAEs (all considered unrelated) 24a
 Malaria 8
 Malaria with cough 1
 Anaemia 4
 Anaemia with sepsis 1
 Pneumonia 1





 Febrile convulsions 1
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In this study, a robust and structured reporting system 
was set up for AE reporting, with the HC staff system-
atically reporting safety observations in patients seen at 
HCs and a trained network of involved and motivated 
CHWs who were encouraged to report all AEs. Despite 
the high rate of follow-up home visits, the reporting rate 
of AEs in this study was lower than that reported in ran-
domized clinical trials of ASAQ Winthrop® in sub-Saha-
ran Africa [7, 10–13]. This finding was not unexpected 
and suggests that community-based AE surveillance 
may be less sensitive than surveillance in the context of 
a clinical trial in an HC. In clinical trials, patients are 
expected to return to the HC every day for the early part 
of the study and then episodically up to 28 days follow-
ing inclusion. At these visits, patients are actively ques-
tioned about the occurrence of AEs. This is likely to elicit 
more reports than when patients are asked only once by a 
CHW, potentially several days after any AE had occurred. 
However, in this study, dedicated home visits allowed a 
higher rate of collection of AEs than non-systematic, 
face-to-face contacts, and in particular with respect to 
unsolicited self-reporting by patients (ten reported AEs 
per 100,000 treatments according to a retrospective study 
of ASAQ combinations in Senegal [20]). Nonetheless, 
the nature of potentially ASAQ-related AEs was similar 
between the present study and previous randomized clin-
ical trials [7, 10–13], suggesting that these are adequately 
detected in the community setting.
It is of note that the rate of AE reporting was highest 
when the interval between treatment initiation and the 
home visit was short and reduction of the mean interval 
before the home visit may increase the sensitivity of AE 
reporting. Although home visits were supposed to take 
place between 3 and 10 days following initiation of treat-
ment, a small number of visits were made before 3 days, 
and documentation of SAEs was proportionally more 
frequent during these visits. It can be hypothesized that 
these early visits may have been triggered by the occur-
rence of AEs, leading to villagers contacting the CHW. 
Nevertheless, if follow-up is too early, there may be a risk 
of missing delayed effects, even if patients were strongly 
encouraged to re-contact their CHW in case of any prob-
lem. In these cases, a further later follow-up visit may 
be useful to ensure comprehensive documentation of all 
AEs.
Comparison of this study with previous cohort-event 
monitoring studies (CEM) of anti-malarial drugs is 
complicated by differences in study design. No previous 
observational CEM study has evaluated the incidence 
of AEs in patients treated specifically with an identified 
ASAQ fixed-dose combination tablet, and several previ-
ous studies have evaluated different anti-malarial drugs 
in the same study. The present study is also much larger 
than previous studies, which included <5000 patients 
(with the exception of one recent multinational study that 
also recruited >10,000 patients [21]). In addition, different 
methods of data collection have been used in these vari-
ous CEM studies. For example, in an early (2006) CEM 
study of AEs in patients receiving anti-malarials in Ghana 
[22, 23], patients were followed up by telephone con-
tact or voluntary return clinic visits; AEs were reported 
in 29% of 2381 patients. However, the study population 
was different from that of this study, being exclusively 
urban and predominantly adult (66.1% aged ≥13  years) 
and the anti-malarial treatment was not restricted to a 
specific anti-malarial medicine (43% of treatments were 
free or fixed combinations of AS and AQ, all brands con-
sidered). In a CEM study of patients treated with AS and 
AQ combinations (various free or fixed formulations over 
time) in rural Senegal, performed between 2001 and 2009 
[24], patients were required to return to the HC every 
day for the 4 days following start of treatment and again 
after 4 weeks, where data on AEs were collected using a 
structured questionnaire. The rate of AEs reporting in 
the study (12%) is close to that observed in the present 
study in Côte d’Ivoire. Other CEM studies of ACT in 
Nigeria [25] and of artemether–lumefantrine (Coartem®) 
in Tanzania [26] also required patients to return to the 
HC or to contact a CHW. The study that is perhaps the 
closest to the present one in design is the INDEPTH 
study of a fixed-dose combination of dihydroartemisinin 
and piperaquine phosphate (Eurartesim®), conducted 
in four African countries between 2013 and 2014 [21], 
which included 11,097 patients with RDT-confirmed P. 
falciparum infections who were followed up by home vis-
its from a CHW or by telephone. More recently, a study 
Table 5 Incidence of adverse events as a function of parasitaemia
The occurrence of adverse events is presented as the incidence rate (%) with its 95% confidence interval
Positive parasitaemia Negative parasitaemia Undetermined parasitaemia p
N = 11,141 N = 3435 N = 585
Any AE 12.9% [12.3%; 13.5%] 13.7% [12.5%; 14.8%] 11.8% [9.2%; 14.4%] 0.333
Any SAE 0.7% [0.5%; 0.8%] 0.6% [0.4%; 0.9%] 0.5% [0.0%; 1.1%] 0.905
Any potentially ASAQ‑related AE 5.6% [5.2%; 6.1%] 5.4% [4.6%; 6.1%] 4.4% [2.8%; 6.1%] 0.423
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in Ghana of patients prescribed ACT [27] has compared 
telephone contact and home visits by a CHW and found 
that the former method elicited more AEs and was less 
expensive to implement. On the other hand, a Nigerian 
study with telephone monitoring which enrolled patients 
buying anti-malarials in a pharmacy reported that, for 
many patients, telephone contact was not maintained 
over time [28].
Overall, 929 AEs potentially related to ASAQ Win-
throp® were reported during 837 episodes (5.5%). The 
most frequent of these potentially related AEs were 
asthenia, somnolence, vomiting, and dizziness, with an 
incidence of >0.5%. All these are known adverse drug 
reactions to ASAQ Winthrop® and listed as such in the 
prescribing information. No cases of retinopathy, symp-
tomatic leukopaenia or symptoms suggestive of serious 
abnormalities in liver function, which are character-
ized AEs associated with amodiaquine, were observed. 
However, no laboratory blood testing was performed, so 
asymptomatic leukopaenia or perturbations of liver func-
tion cannot be ruled out. The incidence of SAEs (0.7%) 
and severe AEs (0.8%) was low and, of the 22 deaths 
reported in the study, none was considered potentially 
related to ASAQ Winthrop®. The nature and frequency 
of SAEs were consistent with previous clinical trials [7, 
10–13]. These findings suggest that SAEs are not under-
reported in the naturalistic setting of this study and that 
the pharmacovigilance procedures implemented by 
the NMCP should be adequate to monitor the safety of 
extensive use of ASAQ Winthrop® in Côte d’Ivoire.
The large sample size of the study (>15,000 malaria 
episodes) was chosen in order to allow identification of 
rare AEs occurring with an incidence of one in 5000. In 
this context, three cases of moderate extrapyramidal dis-
orders (incidence of 0.02%) were recorded and consid-
ered as possibly drug-related. All cases resolved without 
sequelae after treatment with diazepam. Causality could 
not be proven since all patients had also taken non-pre-
scribed traditional medications; furthermore, one patient 
was re-challenged with ASAQ Winthrop® without recur-
rence of symptoms. Prior to the initiation of the study, 
the study sponsor became aware of poorly characterized 
pharmacovigilance reports of extrapyramidal symptoms 
in patients taking amodiaquine or artesunate and amodi-
aquine combinations of different origins and of unknown 
causality. This was the reason why extrapyramidal symp-
toms were listed in the study protocol as an AESI, in an 
effort to better characterize any potential association. 
The identification of three characterized cases in this 
study prompted the Marketing Authorization Holder for 
ASAQ Winthrop® to carry out a comprehensive assess-
ment of the association of extrapyramidal disorders with 
ASAQ Winthrop® or other anti-malarial drugs in 2012, 
which led to extrapyramidal disorders being listed as 
adverse drug reactions in the prescribing information for 
ASAQ Winthrop®. Around the same time, an analysis 
was published of some of the earlier pharmacovigilance 
reports documented in the WHO global pharmacovigi-
lance database (VigiBase™) [29], and there have been fur-
ther subsequent reports of extrapyramidal symptoms in 
patients taking artemisinin and amodiaquine combina-
tions elsewhere in Africa [23, 24, 30].
At the beginning of the study, national malaria treat-
ment recommendations did not require confirmation of 
malaria diagnosis by a blood test, and treatment could 
be initiated on the basis of clinical suspicion only. How-
ever, since malaria symptoms are relatively non-specific, 
this policy exposed patients to unnecessary anti-malar-
ial treatment with a potential risk of toxicity, and was 
changed during the course of the study in 2011, such that 
laboratory confirmation of the diagnosis was required. 
Nonetheless, given the high sensitivity of RDT, false 
positives may still occur in patients with fluctuating low 
parasite densities or carrying residual parasite proteins 
from a previous infection [31–33], in particular in high 
transmission areas such as Côte d’Ivoire. However, even 
before the requirement for RDT, a high rate of biological 
confirmation of suspected malaria was observed (82.6%). 
This is at the high end of the range of published studies 
of the accuracy of clinical diagnosis (40–80%) [34], indi-
cating the quality of clinical assessment by trained and 
supervised health workers. Indeed, all the HC workers 
received training in the differential diagnosis of malaria 
before the study started, and diagnostic practice in each 
HC was supervised by an experienced tropical medicine 
specialist who visited the HC every one to three months. 
The AE profile of ASAQ Winthrop® observed in the 
study did not differ between treated patients with RDT-
confirmed malaria and in patients without identified 
parasitaemia.
Although treatment intake was unsupervised, the rate 
of reported compliance based on tablet count by CHWs 
at home visits was high (97.2%). It is possible that the fact 
that patients were aware that CHWs would be making 
home visits encouraged compliance (or hiding of tablets). 
For some patients, a home visit was made during the 
treatment period, when the CHW could check that the 
treatment was being taken correctly. Nonetheless, any 
such bias is likely to be limited and the good observed 
compliance rate may reflect the ease of administration of 
ASAQ Winthrop®, with a single intake of a low number 
of tablets (one or two) per day. In addition, these tablets 
can be either swallowed or dissolved in a small amount 
of water for people unable to swallow. The good compli-
ance of ASAQ Winthrop® use with prescription recom-
mendations at HCs should be noted, with the prescribed 
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dose being correctly adjusted for a patient’s age in 98.6% 
of episodes.
This study has a number of strengths and limitations. 
The principal strengths relate to the large number of 
patients included and the naturalistic treatment setting. 
The findings should thus be generalizable to every day 
malaria treatment practice in Côte d’Ivoire. In particular, 
the study included essentially all patients with suspected 
malaria treated with ASAQ Winthrop® in the Agboville 
region during the study period, which covered all seasons 
of the year.
The principal limitation related to the lack of system-
atic ascertainment of reported AEs by a physician. Safety 
evaluation was limited to clinical observation, and labo-
ratory testing was only performed on an ad hoc basis. 
In consequence, cases of leukopaenia or impaired liver 
function may have gone undetected if these were asymp-
tomatic. In addition, treatment with ASAQ Winthrop® 
was unsupervised, which means that certain patients may 
not have respected the recommended dosage regimen. 
Finally, a large proportion of patients were prescribed or 
had taken other medications at the same time as ASAQ 
Winthrop® treatment, rendering unambiguous determi-
nation of causality very difficult. However, these limita-
tions are necessary consequences of the naturalistic study 
design.
This type of study may help to extend awareness of the 
use of ACT for malaria treatment and on the importance 
of pharmacovigilance reporting by staff of local HCs 
and by CHWs, and thus contribute to effective long-
term safety monitoring in the NMCP in Côte d’Ivoire. 
A high level of communication was maintained between 
the different partners in the network, which ensured 
that CHWs and local HC staff received information and 
training from the study coordinators whenever the need 
arose. Following this study, the NMCP of Côte d’Ivoire 
signed an agreement with the Drug and Pharmacy Board, 
which states that the latter should undertake training of 
healthcare workers in pharmacovigilance and analysis of 
pharmacovigilance report forms.
This study underlines the added value of systematic 
involvement of CHWs in collecting pharmacovigilance 
data on anti-malarial drugs in a community setting in 
sub-Saharan Africa, at least when new therapeutic pro-
grammes are being implemented. Although the WHO 
has emphasized the need for post-approval safety infor-
mation on new medicines in African countries [35], this 
is particularly challenging in settings where spontaneous 
reporting of adverse drug reactions is low and there is no 
tradition of systematic pharmacovigilance reporting [36]. 
Studies such as this may be an effective and pragmatic 
way to respond to this challenge and to build local capac-
ity in pharmacovigilance.
Conclusion
This large, naturalistic study of the tolerability of ASAQ 
Winthrop® for the unsupervised treatment of uncompli-
cated falciparum malaria under everyday conditions of 
care in Côte d’Ivoire demonstrated that the safety of the 
drug was consistent with what had been seen in the clini-
cal trials, allowed the identification of extrapyramidal 
disorders as rare AEs leading to a change in prescribing 
information, and emphasized the value of involving prop-
erly trained CHWs to collect pharmacovigilance data in 
the field.
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